Distinctions between non-peptide angiotensin II AT1-receptor antagonists

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue SUPPL. 1, 2001, Pages

  Vauquelin, Georges ^a   Fierens, Frederik L P ^a   Verheijen, Ilse ^a   Vanderheyden, Patrick M L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Angiotensin II; CHO cells; Human AT1 receptor; Insurmountable; Non peptide antagonists candesartan

Indexed keywords

EID: 0347785117     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203010020010401     Document Type: Article

References (60)

1. Timmermans PB, Benfield P, Chiu AT, Herblin W, Wong PC. Angiotensin II receptors, functional correlates. Am J Hypertens 1992;5:221S-235S.
2. Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II Receptors, Angiotensin II Receptor Antagonists. Pharmacological Rev 1993;45:205-51.
3. Bumpus FM, Catt KJ, Chiu AT et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991;17:720-1.
4. Mukojama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Molecular cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.
5. Kambayashi Y, Bardhan S, Takahashi K et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-46.
6. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.
7. Zhang JS, Van Meel JCA, Pfaffendorf M, Van Zwieten P. Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein, rabbit aorta; the influence of receptor reserve. J Pharmacol Exp Ther 1993;269:509-14.
8. Robertson MJ. Angiotensin antagonists. In: Leff P (ed). Receptor-based drug design. New York: Marcel Dekker, 1998: 207-23.
9. Liu YJ, Shankley NP, Welsh NJ, Black JW. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible, synoptic action. Br J Pharmacol 1992;106:233-41.
10. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1 receptor subtype. Br J Pharmacol 1993;110:761-71.
11. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.
12. Noda M, Shibouta Y, Inada Y et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol 1993;46:311-18.
13. Mochizuki S, Sato T, Furata K et al. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1995;25:22-9.
14. Wienen W, Mauz ABM, Van Meel JCA, Entzeroth M. Different types of receptor interaction of peptide, nonpeptide angiotensin II antagonists revealed by receptor binding, functional studies. Mol Pharmacol 1992;41:1081-9.
15. de Chaffoy de Courcelles D, Leysen JE, Roevens P, Van Belle H. The serotonin-S2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Development Research 1986;8:173-8.
16. Robertson MJ, Dougall IG, Harper D, Mckechnie KCW, Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci 1994;15:364-69.
17. Dickinson KE, Cohen RB, Skwish S et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol 1994;113:179-89.
18. Wienen W, Hauel N, Van Meel JCA, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52.
19. Olins GM, Chen ST, McMahon EG, Palomo MA, Reitz DB. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol Pharmacol 1994;47:115-20.
20. 1 receptor antagonist. Eur J Pharmacol 1995;283:63-72.
21. 1 receptor antagonist. Br J Pharmacol 1995;114:1117-24.
22. 1 receptor antagonist, UR-7280. Eur J Pharmacol 1996;318:341-7.
23. 1 receptor. Eur J Pharmacol 1997;319:137-46.
24. 1 receptor antagonist Br J Pharmacol 1992;107:1173-80.
25. 1 antagonism. J Pharm Exp Ther 1995;273:753-61.
26. Koh E, Morimoto S, Tomita J et al. Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1994;23:175-9.
27. 1 receptor. J Biol Chem 1995;270:1493-6.
28. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III, VII. J Biol Chem 1997;272:4245-51.
29. 1-receptors. Brit J Pharmacol 1999;126:1057-65.
30. 1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 1999;372:199-206.
31. 1 cells. Biochem Pharmacol 2000;59:927-35.
32. Verheijen I, Fierens FLP, De Backer JP, Vauquelin G, Vanderheyden PML Interaction between the partially insurmountable antagonist valsartan, human recombinant angiotensin II type 1 receptors. Fund Clin Pharmacol 2001;14:577-85.
33. Pendleton RG, Gessner G, Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal, aorta. J Pharmacol Exp Ther 1989;248:637-43.
34. Hara M, Kiyama R, Nakajima S et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol 1995;289:267-73.
35. Rang HP.The kinetic action of acetylcholine antagonists in smooth muscle. Proc R Soc Lond 1965;164:488-510.
36. Rang HP, Dale MM. Mechanisms of drug action. In: Rang HP, Dale MM (eds). Pharmacology. London: Churchill Livingstone, 1987;3-34.
37. Kenakin TP. Drug antagonism. In: Kenakin TP (ed). Pharmacological Analysis of Drug-Receptor Interaction. New York: Raven Press, 1987:205-44.
38. Tamura K, Okuhira M, Mikoshiba I, Hashimoto K. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharmacol Bull 1997;20:850-5.
39. Wong PC, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753. J Pharmacol Exp Ther 1991;258:49-57.
40. 1 receptors, their non-peptide antagonists. Biochem Pharmacol 2001 (in press).
41. 1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol 1999;367:413-22.
42. 3H]-irbesartan to human recombinant angiotensin II type 1 receptors. JRAAS 2000;1:159-65.
43. De Lean A, Stadel J M, Lefkowitz RJ. A ternary complex model explains the agonist-specific properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 1980;255:7108-17.
44. Severne Y, IJzerman A, Nerme V, Zimmernian H, Vauquelin G. Shallow agonist competition binding curves for b-adrenergic receptors: the role for tight agonist binding. Mol Pharmacol 1986;31:69-73.
45. 1 receptor antagonist. J Cardiovasc Pharmacol 1995;25:354-60.
46. Monnot C, Bihoreau C, Conchon S, Curnow KM, Corvol P, Clauser E. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding, coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem 1996;271:1507-13.
47. Cvejic S, Devi LA. Dimerization of the δ-opioid receptor. J Biol Chem 1997;272:26959-64.
48. 2-adrenoceptor on ligand affinity in transgenic mice. Mol Pharmacol 1997;52:187-94.
49. Anderson KM, Murahashi T, Dorstal DE, Peach MJ. Morphological, biochemical analysis of angiotensin II internalisation in cultured rat aortic smooth muscle cells. Am J Physiol 1993;264:C179-C188.
50. 2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997;11:1266-77.
51. 1 receptors in intact cells is apparently unrelated to receptor internalisation. Biochem Pharmacol (submitted)
52. Yu SS, Lefkowitz RJ, Hausdorff WP. β-Adrenergic receptor sequestration: a potential mechanism of receptor resensitization. J Biol Chem 1993;268:337-41
53. Duncia JV, Chiu AT, Carini DJ et al. The discovery of potent nonpeptide angiotensin II receptors antagonists: a new class of potent antihypertensives. J Med Chem 1990;33:1312-29.
54. Inoue Y, Nakamura N, Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997;15:703-14.
55. 1 receptor J Biol Chem 1999;274:7103-10.
56. 1 receptor differently affects the binding of surmountable, insurmountable non-peptide antagonists. JRAAS 2001 (in press).
57. Limbird LE. Cell Surface Receptors: A Short Course on Theory and Methods, 2nd ed. Boston: Kluwer Acad Publ, 1996: 61-122.
58. 1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33:1406-13.
59. Lacourcière Y, Asmar R. A comparison of the efficacy, duration of action of candesartan cilexetil, losartan as assessed by clinic, ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999;12:1181-7.
60. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.